trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Drugs that inhibit the renin-angiotensin-aldosterone system, such as ACE inhibitors and ARBs, can cause potassium retention.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that drugs that inhibit the renin-angiotensin-aldosterone system, such as ACE inhibitors and ARBs, can cause potassium retention?

Yes. Drugs that inhibit the renin-angiotensin-aldosterone system, such as ACE inhibitors and ARBs, are well documented to cause potassium retention, frequently leading to hyperkalemia in vulnerable patient populations.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently confirms that renin-angiotensin-aldosterone system (RAAS) inhibitors (including ACE inhibitors and ARBs) reduce potassium excretion and carry a well-documented risk of hyperkalemia (potassium retention). Multiple papers discuss this as a major clinical side effect or limiting factor in their use.

Evidence for · 5
Association of serum sodium minus chloride level at initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and hyperkalemia in patients with CKD: a case control study
2024
States that hyperkalemia is a well-known side effect of ACE inhibitors and ARBs in patients with chronic kidney disease.
Get citation
Mae, H., Fujimaru, T., Shimoyama, K., Kadota, N., Konishi, K., Itou, Y., Nagahama, M., Taki, F., & Nakayama, M. (2024). Association of serum sodium minus chloride level at initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and hyperkalemia in patients with CKD: a case control study. doi.org. https://doi.org/10.1186/s41100-024-00541-3

See more details
More for · 4
Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.
2026
Discusses agents that inhibit the renin-angiotensin-aldosterone system and notes their propensity to raise potassium levels.
Get citation
S, G., A, V., B, P., & IZ, J. (2026). Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.. doi.org. https://doi.org/10.1161/circresaha.126.327593

Abstract 13512: Patiromer to Manage Hyperkalemia in Patients Receiving Optimized Renin-Angiotensin-Aldosterone System Inhibitors for Heart Failure (DIAMOND): Prespecified Analysis of Patients With Hyperkalemia or Previous Hyperkalemia
2022
Highlights that hyperkalemia or the fear of it frequently complicates renin-angiotensin-aldosterone system inhibitor therapy in heart failure.
Get citation
Coats, A. J. (2022). Abstract 13512: Patiromer to Manage Hyperkalemia in Patients Receiving Optimized Renin-Angiotensin-Aldosterone System Inhibitors for Heart Failure (DIAMOND): Prespecified Analysis of Patients With Hyperkalemia or Previous Hyperkalemia. doi.org. https://doi.org/10.1161/circ.146.suppl_1.13512

New pharmacologic and interventional horizons in hypertension and nondialysis chronic kidney disease: bridging innovation and clinical translation.
2026
Identifies the increased risk of hyperkalemia associated with renin-angiotensin-aldosterone system and mineralocorticoid receptor blockade in chronic kidney disease.
Get citation
A, D., P, I., A, V., E, S., A, S., K, D., D, P., & K, T. (2026). New pharmacologic and interventional horizons in hypertension and nondialysis chronic kidney disease: bridging innovation and clinical translation.. doi.org. https://doi.org/10.1097/hjh.0000000000004439

Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease.
2026
Notes that traditional renin-angiotensin system inhibitors carry well-documented electrolyte risks, specifically regarding potassium elevation.
Get citation
MJ, Y. & S, L. (2026). Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease.. doi.org. https://doi.org/10.5049/ebp.2026.24.e13

What does the evidence say?

The retrieved literature consistently confirms that renin-angiotensin-aldosterone system (RAAS) inhibitors (including ACE inhibitors and ARBs) reduce potassium excretion and carry a well-documented risk of hyperkalemia (potassium retention). Multiple papers discuss this as a major clinical side effect or limiting factor in their use.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work